Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter
- New IMO-9200 data presented at 10th Annual Meeting of the Oligonucleotide Therapeutics Society demonstrate inhibition of TLR-mediated immune responses in multiple preclinical models

CAMBRIDGE, Mass., Oct. 14, 2014 -- Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced it has advanced IMO-9200 into Phase 1 clinical development following acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration.

Published: 14 October 2014
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Idera Pharmaceuticals ( IDRA )

Isoray Announces Early Success for Young Peruvian Girl Utilizing Cesium-131 in First Stereotactic Implant for Inoperable Brain Cancer

7-Year-Old Currently Back in School With No Restrictions and Normal Activities

RICHLAND, WA--(Oct 7, 2014) - IsoRay, Inc. (NYSE MKT: ISR), announced today the excellent results achieved by a young female patient who received Cesium-131 seed via a stereotactic implant for inoperable glioblastoma brain tumor. IsoRay is a medical technology company and innovator in seed brachytherapy, liquid brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic cancer.

In March 2014, a seven year old Peruvian girl was diagnosed with a potentially life-threatening brain cancer known as a glioblastoma multiforme (GBM). The 2.7 cm tumor was located very close to the brainstem, making surgical removal too risky to attempt.

Published: 07 October 2014
Written by Editor
AMEX   Up on News   Project Update  
Read more: IsoRay Inc ( ISR )

RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109

MARLBOROUGH, Mass., Oct. 7, 2014 -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may be effective in suppressing recurrence of hypertrophic scars at the 3-month time point. Patients will continue to be monitored through 9 months to evaluate if this outcome persists over time.

Published: 07 October 2014
Written by Editor
Nasdaq   Project Update  
Read more: RXi Pharmaceuticals Corporation ( RXII )

BioTime’s Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute

- Final Study Enrollment Exceeds 600 Patients -

ALAMEDA, Calif.-- BioTime, Inc. (NYSE MKT: BTX), and its subsidiary OncoCyte Corporation today announced that OncoCyte’s collaborators at The Wistar Institute have completed enrollment of a large, multi-site study evaluating a blood-based lung cancer diagnostic test. OncoCyte previously entered into a Sponsored Research Agreement and a Material Transfer Agreement with The Wistar Institute to collaboratively develop lung cancer diagnostic products approximately one year ago.

Published: 03 October 2014
Written by Editor
AMEX   Up on News   Project Update  
Read more: BioTime Inc ( BTX )

Rockwell Medical Enters Into Exclusive Long-Term Agreement With Baxter Healthcare to Commercialize Rockwell's Hemodialysis Concentrates

Rockwell Receives $20MM Upfront Cash; $15MM Equity Investment; $10MM in Milestone Payments Tied to Manufacturing Expansion

WIXOM, Mich., Oct. 3, 2014 -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has signed an exclusive agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (BAX), to commercialize Rockwell's hemodialysis concentrate product line in the U.S. and in select overseas markets.

Published: 03 October 2014
Written by Editor
Nasdaq   New Product or Order   Up on News  
Read more: Rockwell Medical Inc ( RMTI )
  1. XTL Biopharmaceuticals Ltd ( XTLB )
  2. NanoViricides Inc ( NNVC )
  3. Portola Pharmaceuticals ( PTLA )
  4. Ardelyx Inc ( ARDX )
  5. Major Fallout Stocks After Confirmed Ebola Case in United States